298 related articles for article (PubMed ID: 33799484)
21. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
De SK
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.
Stephens DM; Spurgeon SE
Ther Adv Hematol; 2015 Oct; 6(5):242-52. PubMed ID: 26425337
[TBL] [Abstract][Full Text] [Related]
23. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL; Trněný M; Ribrag V; Zilioli VR; Walewski J; Christensen JH; Delwail V; Rodriguez G; Venugopal P; Coleman M; Dartigeas C; Patti C; Pane F; Jurczak W; Taszner M; Paneesha S; Zheng F; DeMarini DJ; Jiang W; Gilmartin A; Mehta A
EClinicalMedicine; 2023 Aug; 62():102131. PubMed ID: 37599908
[TBL] [Abstract][Full Text] [Related]
24. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
Leukemia; 2024 Mar; ():. PubMed ID: 38454120
[TBL] [Abstract][Full Text] [Related]
25. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
O'Reilly MA; Wilson W; Burns D; Kuhnl A; Seymour F; Uttenthal B; Besley C; Alajangi R; Creasey T; Paneesha S; Elliot J; Gonzalez Arias C; Iyengar S; Wilson MR; Delaney A; Rubio L; Lambert J; Begg K; Boyle S; Cheok KPL; Collins GP; Roddie C; Johnson R; Sanderson R
Hemasphere; 2024 Jun; 8(6):e87. PubMed ID: 38873532
[TBL] [Abstract][Full Text] [Related]
26. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.
Yan F; Jiang V; Jordan A; Che Y; Liu Y; Cai Q; Xue Y; Li Y; McIntosh J; Chen Z; Vargas J; Nie L; Yao Y; Lee HH; Wang W; Bigcal JR; Badillo M; Meena J; Flowers C; Zhou J; Zhao Z; Simon LM; Wang M
Exp Hematol Oncol; 2024 Feb; 13(1):14. PubMed ID: 38326887
[TBL] [Abstract][Full Text] [Related]
27. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.
Thomas CJ; Carvajal V; Barta SK
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792015
[TBL] [Abstract][Full Text] [Related]
28. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Rejeski K; Wang Y; Albanyan O; Munoz J; Sesques P; Iacoboni G; Lopez-Corral L; Ries I; Bücklein VL; Mohty R; Dreyling M; Baluch A; Shah B; Locke FL; Hess G; Barba P; Bachy E; Lin Y; Subklewe M; Jain MD
Am J Hematol; 2023 Nov; 98(11):1699-1710. PubMed ID: 37584447
[TBL] [Abstract][Full Text] [Related]
29. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.
Broccoli A; Casadei B; Morigi A; Sottotetti F; Gotti M; Spina M; Volpetti S; Ferrero S; Spina F; Pisani F; Merli M; Visco C; Paolini R; Zilioli VR; Baldini L; Di Renzo N; Tosi P; Cascavilla N; Molica S; Ilariucci F; Rigolin GM; D'Alò F; Vanazzi A; Santambrogio E; Marasca R; Mastrullo L; Castellino C; Desabbata G; Scortechini I; Trentin L; Morello L; Argnani L; Zinzani PL
Oncotarget; 2018 May; 9(34):23443-23450. PubMed ID: 29805746
[TBL] [Abstract][Full Text] [Related]
30. Frontline Treatment of Mantle Cell Lymphoma.
Ryan CE; Armand P; LaCasce AS
Blood; 2024 Mar; ():. PubMed ID: 38498174
[TBL] [Abstract][Full Text] [Related]
31. Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach.
Chen CJ; Choi MY; Heyman BM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760453
[TBL] [Abstract][Full Text] [Related]
32. New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.
Stancu AL; Smith MR; Almasan A
Discoveries (Craiova); 2014; 2(1):. PubMed ID: 26280017
[TBL] [Abstract][Full Text] [Related]
33. Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma.
Aydilek E; Klein-Scory S; Thomson J; Nilius-Eliliwi V; Vangala D; Schroers R; Wulf G; Mika T
Hemasphere; 2023 Sep; 7(9):e949. PubMed ID: 37654738
[No Abstract] [Full Text] [Related]
34. Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report.
Barrett A; Eyre TA; Bhuva S; Aljurf M; Fakih RE; Ashshi MA; Alshaibani A
EJHaem; 2024 Feb; 5(1):238-241. PubMed ID: 38406527
[TBL] [Abstract][Full Text] [Related]
35. Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia.
Aust Prescr; 2023 Aug; 46(2):40-41. PubMed ID: 38053565
[No Abstract] [Full Text] [Related]
36. Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL.
Killock D
Nat Rev Clin Oncol; 2024 May; ():. PubMed ID: 38789564
[No Abstract] [Full Text] [Related]
37. Cellular Therapies for Mantle Cell Lymphoma.
Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
[TBL] [Abstract][Full Text] [Related]
38. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
von Hundelshausen P; Siess W
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806595
[TBL] [Abstract][Full Text] [Related]
39. Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.
Fürstenau M; Eichhorst B
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809580
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
